
Erlotinib Suppliers & Bulk Manufacturers
Available Forms: Oral Tablets
Available Strengths: 25 mg, 100 mg, 150 mg
Reference Brands: Tarceva® (US & EU)
Category: Oncology Cancer Care
Erlotinib is available in Oral Tablets and strengths such as 25 mg, 100 mg, 150 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Erlotinib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
Technical Specifications & Supply Details | |
---|---|
Lead Time | 7 to 60 days (depending on batch size & schedule) |
MOQ | As per manufacturer’s batch size |
COA | Available with every batch |
Regulatory Dossier / DMF | Available upon request |
Export Documentation | FSC, COA, Manufacturing License, Product Permission |
Standards | IP, BP, USP |
Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Erlotinib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Erlotinib Tablets are a targeted oncology treatment used in the EU and US, primarily indicated for non-small cell lung cancer (NSCLC) with EGFR mutations and advanced pancreatic cancer. As a tyrosine kinase inhibitor (TKI), Erlotinib works by inhibiting the epidermal growth factor receptor (EGFR), slowing cancer cell proliferation. Available in 25 mg, 100 mg, and 150 mg strengths, Erlotinib is marketed under the brand name Tarceva® and widely distributed as a generic formulation across global markets. Pharmaceutical distributors and B2B buyers rely on Erlotinib as a high-value, targeted therapy with well-established clinical efficacy in precision oncology.
Frequently Asked Questions
Related Products
Atezolizumab
Strength:
1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View DetailsDurvalumab
Strength:
120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View DetailsSunitinib
Strength:
12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers